Medical Device Cybersecurity Fleet Management
by Nick Clark | Published April 25, 2026
Medical device cybersecurity moved from guidance into binding statutory law in March 2023, when the Consolidated Appropriations Act amended the Federal Food, Drug, and Cosmetic Act to add Section 524B. Manufacturers of "cyber devices" must now submit a Software Bill of Materials, demonstrate a coordinated vulnerability disclosure process, and provide reasonable assurance that the device and related systems are cybersecure across the full premarket and postmarket lifecycle. The architectural reality is that compliance cannot be satisfied at submission; it must be sustained continuously across deployed fleets that may exceed a million heterogeneous endpoints. Adaptive Query's fleet health monitoring primitive supplies the continuous, credentialed substrate that 524B, the FDA's 2023 premarket cybersecurity guidance, AAMI TIR57, and IEC 81001-5-1 collectively presume but do not themselves construct.
Regulatory and Standards Context
Section 524B of the FD&C Act, added by Section 3305 of the PATCH Act provisions in the Omnibus 2023 legislation, establishes the first statutory definition of a "cyber device" — any device that includes software, has the ability to connect to the internet, and contains technological characteristics that could be vulnerable to cybersecurity threats. Submissions for such devices must include plans to monitor, identify, and address postmarket vulnerabilities and exploits in a reasonable time, design and procedures to ensure cybersecurity through coordinated vulnerability disclosure, and a Software Bill of Materials covering commercial, open-source, and off-the-shelf software components. The FDA's September 2023 final guidance, "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions," operationalizes these statutory hooks by requiring threat modeling, security architecture views, vulnerability assessment artifacts, and SBOM evidence in 510(k), De Novo, and PMA submissions. Postmarket obligations are governed by the FDA's 2016 postmarket cybersecurity guidance, now read in conjunction with 524B's continuous-assurance language.
The standards stack underneath the regulation has hardened in parallel. AAMI TIR57:2016 and its successor work products define risk management for medical device cybersecurity in terms compatible with ISO 14971 safety risk management, while IEC 81001-5-1:2021 and the joint ISO/IEC 81001-5-1 specify secure development lifecycle activities for health software and health IT systems. EU Medical Device Regulation 2017/745 Annex I §17.2 imposes parallel cybersecurity requirements, and the EU Cyber Resilience Act, effective from late 2024 with full obligations in 2027, will layer horizontal product security duties on top. Across these instruments, the recurring architectural premise is that the manufacturer maintains continuous, evidentiary visibility into deployed device state — firmware version, configuration baseline, SBOM composition, observed anomalies — for the entire support window declared in the submission.
The Architectural Requirement
A faithful reading of 524B and the underlying guidance produces a specific architectural shape that is rarely articulated in compliance discourse. The manufacturer must be able to attest, at any moment during the support period, to the integrity and composition of every fielded unit, and must be able to produce that attestation in a form that the FDA's Office of Strategic Partnerships and Technology Innovation (OST), the hospital's clinical engineering department, and a third-party security researcher submitting a CVD report can each consume on terms appropriate to their role. The attestation must bind the running firmware to a specific SBOM, bind that SBOM to a specific submission cleared under a specific 510(k) or PMA number, and bind any field configuration change to an authenticated change-management event. None of these bindings can be reconstructed retroactively from logs after a recall — they have to exist at the moment the regulator asks for them, often years after deployment.
The hospital side imposes a complementary requirement. Under the Joint Commission's environment of care standards, NIST SP 800-66 HIPAA Security Rule guidance, and increasingly under hospital cyber insurance underwriting, biomedical engineering departments must inventory, segment, and continuously monitor connected medical devices on their networks. The MDS2 (Manufacturer Disclosure Statement for Medical Device Security) form, now in its 2019 revision under HSCC guidance, has shifted from a static disclosure document into an expected feed of live security posture. A hospital running 80,000 connected devices from 300 manufacturers cannot reasonably operate 300 disjoint OEM portals; it needs a uniform, credentialed substrate over which any manufacturer can publish device-health attestations and any clinical engineering tool can consume them.
Why Procedural Compliance Fails
The dominant industry response to 524B has been to layer procedural compliance — written policies, periodic vulnerability scans, manually maintained SBOM spreadsheets, ticket-based CVD intake — on top of pre-existing OEM device management portals. This pattern fails for three structural reasons. First, the SBOM is not authoritative: it is a document produced at build time, copied into the submission, and then drifts as field firmware updates occur, third-party libraries are patched out of band, and supplier components are silently substituted. By the time a Log4Shell-class vulnerability lands, the manufacturer cannot answer the regulator's first question — "which fielded units contain the affected component?" — without weeks of forensic reconstruction.
Second, integrity claims are unverifiable. A device that reports its own firmware hash over an authenticated channel is still subject to the classic confused-deputy problem: malware on the device can report whatever hash it likes. Genuine integrity attestation requires a hardware root of trust, and increasingly a Physical Unclonable Function (PUF) or equivalent device-bound key that cannot be cloned by an attacker who has captured the firmware image. Procedural controls — "the device shall report its firmware version" — do not constrain the adversary, because the adversary controls the device. Third, cross-stakeholder evidence does not compose. The OEM's portal, the hospital's CMMS, the FDA's submission docket, and the CVD researcher's email thread are four disjoint evidentiary surfaces; reconciling them during a recall or an MDR-reportable incident is an operations problem that no amount of policy can dissolve.
What the AQ Fleet-Health Primitive Provides
The fleet health monitoring primitive treats every fielded device as a continuous publisher of credentialed observations against a tamper-evident substrate. Each device boots through a measured boot sequence rooted in a hardware PUF or TPM-equivalent, producing a device-integrity attestation that binds the running image to the device's unforgeable identity. That attestation is published to the governance chain alongside an SBOM attestation that resolves, by content hash, to the specific component manifest cleared under the device's premarket submission. Tamper-evident seals — both physical, where service-port intrusion is detected, and logical, where unexpected configuration deltas are flagged — produce credentialed events on the same substrate, so that any deviation from the cleared baseline is observable in real time rather than discovered during forensic review.
Zero-trust device management replaces the OEM portal pattern with a credentialed federation in which the manufacturer, the hospital biomedical department, the FDA, and approved security researchers each hold scoped credentials over the same evidentiary substrate. A vulnerability disclosure submitted by an external researcher attaches as a credentialed observation against the affected SBOM attestation; the manufacturer's coordinated response, the patched firmware's new attestation, and the rollout telemetry across the fleet all chain together as lineage-bound events. When the regulator asks "which units are affected and which have been remediated," the answer is a query against the substrate, returned with cryptographic provenance, rather than a spreadsheet reconstructed under deadline pressure.
Compliance Mapping
The mapping from primitive to regulation is direct. Section 524B(b)(1)'s requirement to "monitor, identify, and address" postmarket vulnerabilities is satisfied by the continuous attestation stream and the credentialed CVD intake channel; the "reasonable time" standard becomes auditable because every step in the response is timestamped and chained. Section 524B(b)(3)'s SBOM requirement is satisfied by the SBOM attestation bound to each cleared submission, with field drift detected as an attestation mismatch rather than discovered through periodic spreadsheet reconciliation. The FDA premarket guidance's threat-model and security-architecture view requirements remain submission-time artifacts, but they gain operational teeth because the primitive can demonstrate that the cleared architecture is in fact the deployed architecture.
IEC 81001-5-1's secure development lifecycle controls map onto the build-time and release-time attestations that feed the substrate. AAMI TIR57's risk management requirements map onto the credentialed risk-event stream. The MDR Annex I §17.2 cybersecurity requirements and the forthcoming EU CRA obligations consume the same substrate through declared cross-jurisdiction federation, with hospital-side MDS2 consumption handled by scoped credentials issued to clinical engineering. NIST SP 800-66 HIPAA Security Rule expectations on the covered entity side are satisfied by the same substrate viewed from the hospital's vantage, eliminating the OEM-portal proliferation that currently defeats reasonable network defense.
Adoption Pathway
Adoption does not require a forklift replacement of existing device management infrastructure. The pragmatic entry point is a single high-volume product line approaching its next 510(k) or De Novo submission, where the manufacturer can stand up the attestation publishing path as part of the cybersecurity submission artifacts and run it in parallel with existing telemetry. Hardware roots of trust on next-revision boards, an SBOM attestation pipeline integrated with the existing build system, and a credentialed CVD intake endpoint can be operational within a single submission cycle. Existing fielded units accept attestation through firmware update where hardware permits, and remain on legacy telemetry where it does not, with the substrate accommodating both populations.
Hospital-side adoption begins with a single integrated delivery network's clinical engineering department subscribing to the substrate as a credentialed observer, replacing one OEM portal at a time as manufacturers publish through the federation. The FDA participates as a credentialed regulatory observer with read scope across submission-bound attestations, eliminating the recall-time evidence reconstruction that currently dominates post-market cybersecurity operations. Within two to three submission cycles the substrate becomes the path of least resistance for new clearances, and the procedural-compliance overhead that currently consumes manufacturer cybersecurity budgets is displaced by structural evidence the regulator and the hospital can both verify on demand.
